The acylated form of protein D of Haemophilus influenzae is more immunogenic than the nonacylated form and elicits an adjuvant effect when it is used as a carrier conjugated to polyribosyl ribitol phosphate.
The nonacylated form of protein D (PDm) of Haemophilus influenzae has been shown to induce the production of antibodies that are bactericidal to homologous and heterologous nontypeable H. influenzae (NTHi) strains. In this study, immunization of rats with lipoprotein D (LPD) induced higher levels of anti-protein D immunoglobulin G and A serum antibodies than immunization with PDm, and the bactericidal activities of sera from LPD-immunized rats were greater than those of sera from PDm-immunized rats. Immunization with LPD or PDm did not prevent the development of acute otitis media (AOM) when rats were challenged with 10(4) CFU of an NTHi strain. However, on the eighth day of bacterial challenge, 50% (5 of 10) of LPD-immunized rats had recovered from otitis media and 30% (3 of 10) had negative middle ear cultures, whereas only 30% (3 of 10) of PDm-immunized rats had recovered, though none was culture positive. Immunization with an inactivated homologous bacterial strain elicited 70% protection (i.e., 7 of 10 rats) in the rat otitis media model. LPD and PDm were also conjugated to the H. influenzae type b (Hib) capsular polysaccharide, polyribosyl ribitol phosphate (PRP), to test protein D-conjugated PRP vaccine's potential for protection against Hib infection. When two LPD-conjugated and two PDm-conjugated PRP vaccines, each containing a different protein concentration, and a tetanus toxoid-conjugated vaccine (ACT-HIB) were tested in the experimental model of rat otitis induced with a Hib strain (Minn A), both of the LPD-conjugated and one of the PDm-conjugated vaccines induced significant protection from AOM, the level of protection being highest in animals given the vaccine with the highest LPD content. Sera from these rats also manifested the highest anti-PRP and anti-LPD antibody levels and the highest bactericidal activities against a Hib strain and an NTHi strain.
Akkoyunlu
M
M
Department of Medical Microbiology, University of Lund, Malmö University Hospital, Sweden. Mustafa.Akkoyunlu@Yale.edu
Melhus
A
A
Capiau
C
C
van Opstal
O
O
Forsgren
A
A
D000215:Acylation; D000276:Adjuvants, Immunologic; D000818:Animals; D001426:Bacterial Proteins; D001428:Bacterial Vaccines / Q000276:immunology; D002352:Carrier Proteins / Q000737:chemistry / Q000276:immunology*; D006193:Haemophilus influenzae / Q000276:immunology*; D007072:Immunoglobulin D; D008074:Lipoproteins / Q000737:chemistry / Q000276:immunology*; D011134:Polysaccharides / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology; D051381:Rats
D000276:Adjuvants, Immunologic; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D002352:Carrier Proteins; D007072:Immunoglobulin D; D008074:Lipoproteins; D011134:Polysaccharides; D011135:Polysaccharides, Bacterial; C008984:polyribitol phosphate; C067989:glpQ protein, Haemophilus influenzae